NCT00310180 2026-03-18
TAILORx
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
21 trialsNCT01272037 2026-03-18
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00893061 2026-03-17
MNEMOSYNE
Centre Oscar Lambret
Phase 3 Completed
NCT06072781 2026-03-17
RAMP 301
Verastem, Inc.
Phase 3 Recruiting
NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT06016738 2026-03-13
OPERA-01
Olema Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT04886531 2026-03-12
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06218303 2026-03-12
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
University of Pittsburgh
Phase 1 Recruiting
NCT07174336 2026-03-06
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT06671912 2026-03-04
LoTam
Alliance for Clinical Trials in Oncology
Phase 3 Suspended
NCT04852887 2026-03-03
DEBRA
NRG Oncology
Phase 3 Recruiting
NCT05307705 2026-03-02
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT05768139 2026-03-02
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT02767661 2026-02-27
MECCA
Sun Yat-sen University
Phase 3 Completed
NCT05467891 2026-02-27
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT06179303 2026-02-27
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT03179904 2026-02-24
TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT04059484 2026-02-24
AMEERA-3
Sanofi
Phase 2 Terminated
NCT05896566 2026-02-24
PREcoopERA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT06507618 2026-02-24
POWER II
University of Virginia
Phase 3 Recruiting